Nektar Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nektar Therapeutics's estimated annual revenue is currently $100.4M per year.
- Nektar Therapeutics received $175.0M in venture funding in October 2016.
- Nektar Therapeutics's estimated revenue per employee is $168,107
- Nektar Therapeutics's total funding is $1.2B.
- Nektar Therapeutics's current valuation is $2.2B. (January 2022)
Employee Data
- Nektar Therapeutics has 597 Employees.
- Nektar Therapeutics grew their employee count by -2% last year.
Nektar Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Sr. VP Clinical Development Operations | Reveal Email/Phone |
3 | VP Head Clinical Development | Reveal Email/Phone |
4 | SVP Information Technology | Reveal Email/Phone |
5 | SVP, HR and Facilities Operations | Reveal Email/Phone |
6 | VP, Commercial Head Europe | Reveal Email/Phone |
7 | VP Oncology Research | Reveal Email/Phone |
8 | Head Clinical Pharmacology and Quantitative Sciences | Reveal Email/Phone |
9 | VP, Pharmaceutical Operations | Reveal Email/Phone |
10 | VP, Financial Planning & Analysis | Reveal Email/Phone |
Nektar Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Nektar Therapeutics?
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$1.2B
Total Funding
597
Number of Employees
$100.4M
Revenue (est)
-2%
Employee Growth %
$2.2B
Valuation
N/A
Accelerator
Nektar Therapeutics News
Nektar Therapeutics has announced a new strategic plan focused on prioritizing key research and development efforts that will be most...
On Monday, Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce.
Nektar Therapeutics is a biopharmaceutical company focused on the development of investigational medicines in oncology, immunology, and...
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively sti ...
SAN FRANCISCO, May 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC). NKTR-255 is a novel recombinant human Interleu ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $110.3M | 599 | 22% | $157.1M |
#2 | $102.9M | 601 | 5% | $333M |
#3 | $203.2M | 602 | 8% | N/A |
#4 | $121.4M | 607 | 6% | N/A |
#5 | $75M | 608 | -24% | N/A |
Nektar Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2005-08-17 | $24.0M | Undisclosed | Article | |
| 2005-09-23 | $Undisclosed | Undisclosed | Article | |
| 2011-01-19 | $Undisclosed | Undisclosed | Jefferies & Company Inc | Article |
| 2012-07-12 | $125.0M | Undisclosed | Cowen and Company LLC, CRT Capital Group LLC | Article |
| 2014-01-22 | $Undisclosed | Undisclosed | J.P. Morgan | Article |
| 2015-10-07 | $250.0M | Undisclosed | TPG Special Situations Partners | Article |
| 2016-06-03 | $20.0M | Undisclosed | Daiichi Sankyo | Article |
| 2016-10-18 | $175.0M | Undisclosed | Article |